Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EIF2AK4 | Q9P2K8 | 2/20 | 0.48 |
| ▸ | FLT3 | P36888 | 5/20 | 0.44 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.40 |
| ▸ | EGFR | P00533 | 2/20 | 0.40 |
| ▸ | AURKA | O14965 | 5/20 | 0.39 |
| ▸ | CDK1 | P06493 | 4/20 | 0.39 |
| ▸ | CCNB1 | P14635 | 4/20 | 0.39 |
| ▸ | CDK4 | P11802 | 5/20 | 0.39 |
| ▸ | CCND1 | P24385 | 5/20 | 0.39 |
| ▸ | CCND2 | P30279 | 5/20 | 0.39 |
| ▸ | CCND3 | P30281 | 5/20 | 0.39 |
| ▸ | GSK3A | P49840 | 2/20 | 0.36 |
| ▸ | GSK3B | P49841 | 2/20 | 0.36 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1355845 | 0.90 | EIF2AK4 (0.60) | EIF2AK4FLT3TBK1EGFRAURKA | |
| SCHEMBL1355490 | 0.86 | EIF2AK4 (0.47) | EIF2AK4FLT3TBK1EGFRAURKA | |
| SCHEMBL1356177 | 0.86 | EIF2AK4 (0.47) | EIF2AK4FLT3TBK1EGFRAURKA | |
| SCHEMBL3605767 | 0.83 | WEE1 (0.44) | EIF2AK4FLT3AURKACDK1CCNB1 | |
| SCHEMBL1355988 | 0.79 | FLT3 (0.64) | EIF2AK4FLT3TBK1EGFRAURKA | |
| SCHEMBL3587383 | 0.76 | DCLK1 (0.39) | EIF2AK4FLT3AURKACDK1CCNB1 | |
| SCHEMBL1356702 | 0.76 | EIF2AK4 (0.56) | EIF2AK4FLT3TBK1EGFRAURKA | |
| SCHEMBL1356098 | 0.75 | EIF2AK4 (0.62) | EIF2AK4FLT3TBK1EGFRCDK4 | |
| SCHEMBL3588130 | 0.74 | AURKA (0.39) | EIF2AK4FLT3AURKACDK1CCNB1 | |
| SCHEMBL1356186 | 0.74 | EIF2AK4 (0.67) | EIF2AK4FLT3TBK1EGFRAURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110281821-A9 | Modulators of Mitotic Kinases | BIOGEN IDEC MA INC. (US) | 2011-11-17 | — | — | US | claimed |
| US-20100249067-A1 | Modulators of Mitotic Kinases | BIOGEN IDEC MA INC. (US) | 2010-09-30 | — | — | US | claimed |
| EP-2108020-A2 | 1-H-PYRAZOLO[3,4B]PYRIMIDINE DERIVATIVES AND THEIR USE AS MODULATORS OF MITOTIC KINASES | Biogen Idec MA, Inc. (US) | 2009-10-14 | — | — | EP | claimed |
| WO-2008094602-A2 | 1-H-PYRAZOLO (3,4B) PYRIMIDINE DERIVATIVES AND THEIR USE AS MODULATORS OF MITOTIC KINASES | BIOGEN IDEC MA INC. (US) | 2008-08-07 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249067-A1 | Modulators of Mitotic Kinases | BUB1, BUB1B, CDK1 | EIF2AK4 791/4885FLT3 766/4885TBK1 1295/4885 |
| US-20110281821-A9 | Modulators of Mitotic Kinases | BUB1, BUB1B, CDK1 | EIF2AK4 791/4885FLT3 766/4885TBK1 1295/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.